LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.29 -3.73

Buy Sell

Overview

Share price change

24h

Current

Min

1.28

Max

1.37

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+69.17% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-20M 155M
Previous open	5.02
Previous close	1.29

News Sentiment

By Acuity

20%

80%

26 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 mar 2026, 20:38 UTC

Earnings

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mar 2026, 23:57 UTC

Market Talk

Global Equities Roundup: Market Talk

10 mar 2026, 23:57 UTC

Market Talk

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mar 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mar 2026, 23:35 UTC

Market Talk

Major News Events

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mar 2026, 23:06 UTC

Earnings

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mar 2026, 22:51 UTC

Major News Events

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mar 2026, 21:39 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mar 2026, 21:21 UTC

Earnings

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mar 2026, 21:15 UTC

Earnings

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mar 2026, 21:15 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mar 2026, 21:14 UTC

Earnings

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mar 2026, 21:13 UTC

Earnings

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mar 2026, 21:12 UTC

Earnings

Franco-Nevada 4Q Rev $597.3M >FNV

10 mar 2026, 21:12 UTC

Earnings

Franco-Nevada 4Q EPS $1.90

10 mar 2026, 20:57 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

10 mar 2026, 20:44 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:34 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

10 mar 2026, 20:34 UTC

Market Talk

Earnings

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mar 2026, 20:23 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:16 UTC

Earnings

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mar 2026, 20:14 UTC

Earnings

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mar 2026, 20:14 UTC

Earnings

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mar 2026, 20:13 UTC

Earnings

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mar 2026, 20:12 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

69.17% upside

12 Months Forecast

Average 2.25 USD 69.17%

High 2.5 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

26 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.